Programme at a Glance - 56th EASD Annual Meeting
Programme at a Glance - 56th EASD Annual Meeting
Tuesday, 22 September 2020
Vienna Hall | Linz Hall | Graz Hall | Salzburg Hall | Innsbruck Hall | Klagenfurt Hall | |
| 08:40 08:45 | Opening #EASD2020 | |||||
| 08:45 09:15 | Presidential Address | |||||
| 09:15 10:00 | 52nd Claude Bernard Lecture | |||||
| 10:15 11:45 | OP 1 | OP 2 | OP 3 | OP 4 | OP 5 | OP 6 |
| 12:00 13:00 | Poster Event A | |||||
| 13:15 14:15 | Poster Event B | |||||
| 14:30 16:00 | OP 7 | OP 8 | OP 9 | OP 10 | OP 11 | OP 12 |
| 16:15 17:15 | 35th Camillo Golgi Lecture | 14th Albert Renold Lecture 16:55 - 17:55 | ||||
| 17:15 17:55 | ||||||
| 18:10 19:10 | EASD General Assembly | |||||
Wednesday, 23 September 2020
Vienna Hall | Linz Hall | Graz Hall | Salzburg Hall | Innsbruck Hall | Klagenfurt Hall | |
| 08:30 10:00 | EASD/ADA Symposium: ADA/EASD Precision medicine in diabetes initiative | EASD/ESC Symposium: The dawn of CV risk reduction in type 2 diabetes: 5 years of SGLT2i CV outcome trials | Sweet pregnancy | Human islet transcriptomes to gain insight into diabetes: promises and pitfalls | The LIBERATES Trial | |
10:15 | OP 13 | OP 14 | OP 15 | OP 16 | OP 17 | OP 18 |
| 12:00 13:00 | Poster Event C | |||||
| 13:15 14:15 | Poster Event D | |||||
| 14:30 16:00 | OP 19 | OP 20 | OP 21 | OP 22 | OP 23 | OP 24 |
| 16:15 17:15 | EASD-Novo Nordisk Foundation Diabetes Prize for Excellence | |||||
| 17:30 18:30 | What is the future of type 1 diabetes treatment? | Diabetes in primary care | VERTIS CV outcome | Diabetes and cancer | Multi-dimensional roles of ketone bodies in fuel metabolism, signalling, and therapeutics | An easy to digest guide to precision nutrition |
Thursday, 24 September 2020
Vienna Hall | Linz Hall | Graz Hall | Salzburg Hall | Innsbruck Hall | Klagenfurt Hall | |
| 08:30 10:00 | Diabetologia Symposium 2020: The pancreas in health and in diabetes | Advances in the pathogenesis and treatment of diabetic complications: going beyond the usual | The important conversation between the heart and the kidney | We are what we do not eat | Rising Star Symposium 08:20 - 10:00 | Empagliflozin for the treatment of chronic heart failure and a reduced ejection fraction in patients with and without diabetes: new results of the EMPEROR-Reduced trial |
| 10:15 11:45 | OP 25 | OP 26 | OP 27 | OP 28 | OP 29 | OP 30 |
| 12:00 13:00 | Poster Event E | |||||
13:15 | Poster Event F | |||||
14:30 | OP 31 | OP 32 | OP 33 | OP 34 | OP 35 | OP 36 |
| 16:15 17:00 | Induction of Honorary Members 55th Minkowski Lecture | |||||
| 17:15 18:15 | Do we need surveillance of the liver of type 2 diabetes patients? | New approaches to reducing hypoglycaemia: hype or hope | When your medicine gives you diabetes | New lessons about diabetic complications: 30 years and counting in the DCCT/EDIC | Closing the loop: commercial systems or open source? | |
Friday, 25 September 2020
Vienna Hall | Linz Hall | Graz Hall | Salzburg Hall | Innsbruck Hall | Klagenfurt Hall | |
08:30 | Comprehensive approaches with novel biomarkers for predicting purposes | EASD/JDRF Symposium: Human iPSC-derived cells, the state-of-the-art to model diabetes | Targeting the gut to treat diabetes | Uric acid: a biomarker or risk factor for disease - the answer is here! | The role of altered lipid handling in diabetes | Michael Berger Debate: ESC vs EASD/ADA-guidelines on diabetes and cardiovascular disease: Same evidence but different interpretations - who’s right? |
| 09:45 10:45 | OP 37 | OP 38 | OP 39 | OP 40 | OP 41 | OP 42 |
| 11:00 12:00 | OP 43 | OP 44 | OP 45 | OP 46 | OP 47 | OP 48 |
| 12:15 13:45 | Diabetes on the run: insulin therapy in type 1 diabetes and exercise | Innovative medicines initiative (IMI): the power of public private partnerships in diabetes research | Assessing the true burden of hypoglycaemia | A gender-sensitive approach pays off in diabetes | EASD/AASD Symposium: Implementation science in diabetes |
Programme may be subject to change.
Non-commercial satellite symposia on the occasion of the 56th EASD Annual Meeting:
Tuesday, | Novel biomarkers for type 2 diabetes |